Back to News
Market Impact: 0.4
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
Source: zacks.com
Healthcare & BiotechCorporate EarningsCompany FundamentalsCorporate Guidance & Outlook
Recursion reported promising clinical data for REC-4881 and REC-1245 and beat Q3 earnings estimates. Disciplined spending extends its cash runway into 2029; the article provides no figures for the earnings beat or clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings